cbdMD, Inc. To Host Conference Call to Discuss September 30, 2024 Fourth Quarter and Fiscal Year 2024 ResultsDecember 12, 2024 12:13 PM EST | Source: cbdMDCharlotte, North Carolina--(Newsfile Corp. - December 12, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA) one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Tuesday, December 17, 2024, to discuss the company's Se ...

. ● . cbdMD, Inc. Announces Acceptance of Compliance Plan by NYSE American August 26, 2024 4:25 PM EDT | Source: cbdMD Charlotte, North Carolina--(Newsfile Corp. - August 26, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD-PA), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with its functional mushroom brand ATRx Labs, today announced that it received notice from the NYSE American LLC that it ha ...

● . . cbdMD Delivers on Sequential Revenue Growth and Positive Net Income for Q3 2024 cbdMD Achieves Significant Reduction in Operating Loss as Operational Efficiencies Significantly Improve in Q3 2024 August 14, 2024 4:10 PM EDT | Source: cbdMD Charlotte, North Carolina--(Newsfile Corp. - August 14, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD-PA) one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, alo ...

Financial Performance - Total net sales for the three months ended June 30, 2024, were $5.17 million, a decrease of $0.95 million or 16% compared to $6.12 million in the same period of 2023[113] - For the nine months ended June 30, 2024, total net sales were $14.93 million, down $3.52 million or 19.1% from $18.44 million in the same period of 2023[113] - The company reported a net loss attributable to common shareholders of $(540,763) for Q2 2024, a substantial improvement from $(2,770,904) in Q2 2023[113] Sales Channels - E-commerce sales accounted for 76.1% of total net sales in Q2 2024, down from 81.7% in Q2 2023, while wholesale sales increased to 23.9% from 18.3%[114] Profitability and Margins - The company achieved a gross profit margin of 65.8% for Q2 2024, an increase of 2.9% from 62.8% in Q2 2023[113] - Adjusted EBITDA for the three months ended June 30, 2024, was $(84,953), compared to $(608,354) for the same period in 2023, indicating an improvement in core operating results[134] Operating Costs and Expenses - Operating loss from operations improved to $(382,028) in Q2 2024, a significant reduction of $1.44 million compared to $(1,823,652) in Q2 2023[113] - Total operating expenses decreased by approximately $1.9 million or 24% for the three months ended June 30, 2024, compared to the same period in 2023, driven by reductions in staff-related expenses and advertising[120] - Year-to-date operating expenses for the nine months ending June 30, 2024, decreased by $6.1 million, reflecting management's focus on operational efficiencies[121] - Cost of sales as a percentage of net sales remained stable at 35% for both the three months ended June 30, 2024, and 2023, attributed to ongoing cost-saving initiatives[117] Cash Flow and Capital Management - The company had cash and cash equivalents of $2.3 million and negative working capital of $567,610 as of September 30, 2023[124] - The company entered into a securities purchase agreement on January 30, 2024, raising $1,250,000 in gross proceeds for working capital and general corporate purposes[126] - Management believes that quarterly cash consumption should continue to improve in subsequent quarters, despite a net cash use of $0.1 million for the three months ended June 30, 2024[128] - The company has suspended cash dividend payments and is accruing dividends on a monthly basis, with an annual rate of 8% payable to preferred shareholders[126] Strategic Initiatives - The company launched a new functional mushroom product line under the ATRx brand in December 2023, expanding its product offerings[102] - The company is focused on reducing operating costs, achieving over $200,000 in monthly savings as of August 2024 through various cost-saving initiatives[107] - The company plans to increase marketing spend in Q4 2024 to support revenue growth despite ongoing cost reductions[107] - The company is exploring international expansion opportunities, particularly in Central and South America, and has gained market share through sanitary registration approvals[110] Financial Reporting and Compliance - The value of the non-cash contingent liability was $90,363 at September 30, 2023, with no ongoing liability recorded after the final issuance of shares in January 2024[123] - The company has no undisclosed off-balance sheet arrangements that could materially affect its financial condition or results of operations[139] - The term "off-balance sheet arrangement" refers to transactions or agreements with unconsolidated entities that may involve guarantees or contingent interests[139] - The company is classified as a smaller reporting company, thus quantitative and qualitative disclosures about market risk are not applicable[140]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to _______________ Commission file number 001-38299 cbdMD, INC. (Exact Name of Registrant as Specified in its Charter) North Carolina 47-34 ...

Table of Contents ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to _______________ Commission file number 001-38299 cbdMD, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) (Exact Name of Registrant as Specified in its Charter) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________ Commission file number 001-38299 cbdMD, INC. (Exact Name of Registrant as Specified in its Charter) North Carolina 47-3414576 State or Oth ...

Table of Contents ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to _______________ Commission file number 001-38299 cbdMD, INC. (Exact Name of Registrant as Specified in its Charter) Nor ...

cbdMD, Inc. (NYSE:YCBD) Q2 2023 Earnings Conference Call May 15, 2023 4:15 PM ET Company Participants Brad Whitford - VP of Finance Ronan Kennedy - Interim Chief Executive Officer and Chief Financial Officer Sibyl Swift - Chief Science Officer & VP Regulatory Affairs Conference Call Participants Anthony Vendetti - Maxim Group Operator Good afternoon. Welcome to cbdMD's, Inc. March 31, 2023, Second Quarter of Fiscal '23 Earnings Call and Update. This afternoon, the company issued a press release that provide ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to _______________ Commission file number 001-38299 cbdMD, INC. (Exact Name of Registrant as Specified in its Charter) No ...